

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



PuraPharm

PURAPHARM CORPORATION LIMITED

培力農本方有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1498)

APPOINTMENT OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. LEUNG Stephen Kwok Keung (梁國強) (“**Mr. Leung**”) has been appointed as a non-executive Director of the Company with effect from 14 June 2023.

The biographical details of Mr. Leung are set out below:

Mr. Leung, aged 67, has over 35 years of extensive experience in disease management, industrial marketing and strategic planning.

Mr. Leung started his distinguished career at Pfizer Hong Kong, the country office of Pfizer Inc. (“**Pfizer**”) as a sales representative in 1983 and was transferred to Pfizer Australia as a product manager in 1986. In 1991, he was promoted to the Pfizer’s New York Headquarters as an international marketing manager. In 1994, Mr. Leung was transferred back to Pfizer Australia as a sales and disease management manager before returning to Hong Kong as a country manager of Pfizer Hong Kong in 1997. Mr. Leung then retired from Pfizer in March 2022 and under his leadership, Pfizer Hong Kong has won the prestigious HKMA Quality Gold Award, Outstanding Corporate Citizenship Gold Award and Best Companies to Work for in Asia.

Over the decades, Mr. Leung has been actively serving the Hong Kong community in various capacities including (i) the chairman of School of Pharmacy Advisory Board and member of Consultative Committee of the School of Nursing in The Chinese University of Hong Kong; (ii) member of the Incorporated Management Committee in The Hong Kong Management Association K S Lo College; (iii) council members of various associations including The Hong Kong Management Association (the “**HKMA**”), Hong Kong College of Health Service Executives (“**HKCHSE**”), College of Pharmacy Practice (“**CPP**”) and the Common Purpose Hong Kong; and (iv) ex-member of each of the Advisory Council on Food and Environmental Hygiene and Council on Human Reproductive Technology in Hong Kong. Mr. Leung is also a Fellow of each of the HKMA, HKCHSE, CPP and The Australasian College of Health Service Management.

Mr. Leung was honoured with the Asia Coaching Leadership Excellence Award in 2015, the Leader of the Year Award in 2016 and the Exemplary Leader Award in 2021, recognizing his visionary leadership and unremitting contribution to the industry. Mr. Leung received a bachelor’s degree in pharmacy from John Moore University in the United Kingdom and a master’s degree in business (marketing) from The University of Manchester Institute of Science and Technology in the United Kingdom in 1979 and 1982 respectively. He is also a registered pharmacist in Hong Kong and the United Kingdom as well as a certified executive coach with The Worldwide Association of Business Coaches and International Coaching Federation.

The Company has entered into a letter of appointment with Mr. Leung in relation to his appointment as a non-executive Director of the Company. He has been appointed for a term of three years, with effect from 14 June 2023. Mr. Leung will hold the office until the forthcoming annual general meeting of the Company and shall then be eligible for re-election in accordance with the articles of association of the Company. He is entitled to a director’s fee in the amount of HK\$200,000 per annum, which has been recommended by the remuneration committee of the Board and approved by the Board, having considered his qualifications, duties, responsibilities and expertise expected to be devoted to the Company’s affairs, the Company’s remuneration policy and the prevailing market conditions.

Save as disclosed above, as at the date of this announcement, Mr. Leung (i) does not hold any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); (ii) does not have any relationship with any other Directors, senior management or substantial or controlling shareholders of the Company within the meaning of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”); (iii) does not hold any other position in the Group; (iv) does not hold any directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; and (v) does not hold any other major appointment and professional qualification.

Save as disclosed above, there is no other information relating to the appointment of Mr. Leung which shall be disclosed pursuant to Rule 13.51(2) of the Listing Rules and there are no other matters that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Company would like to welcome Mr. Leung in joining the Board.

By Order of the Board
PuraPharm Corporation Limited
Chan Yu Ling, Abraham
Chairman

Hong Kong, 14 June 2023

As at the date of this announcement, the executive Directors of the Company are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Norimoto Hisayoshi; the non-executive Director of the Company is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors of the Company are Mr. Ho Kwok Wah, George, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.